Repligen Corporation (RGEN) SEC Filings & Earnings Calls

Integration risk: Repligen must successfully integrate BioLife's operations and realize expected synergies.

“Over the past several months, our teams have worked closely together to develop a thoughtful integration plan... we are even more excited about the strategic rationale.” · word for word

Cell therapy market growth dependency: Acquisition's success relies on continued expansion of cell therapy market.

“BioLife's highly-differentiated portfolio of products expands our presence in the rapidly growing cell therapy market.” · word for word

Merger completion risk remains due to stockholder approval and other customary conditions; integration risk post-close.

“Completion remains subject to adoption by BioLife's stockholders and other closing conditions.”

Restructuring execution risk

“The Company expects to identify additional actions as it further refines its initiatives in future periods.” · word for word

Customer concentration

“There was no revenue from a specific customer that represented 10% or more of the Company's total revenue for the three and six months ended June 30, 2026 or 2025.” · word for word

GAAP EPS declined significantly due to acquisition-related costs and other adjustments.

“Q2 EPS was $0.09 on a fully diluted basis, compared to $0.26.” · word for word

Pending acquisition of BioLife Solutions introduces integration risk and potential dilution.

“The announcement of our definitive agreement to acquire BioLife Solutions is a key milestone in our company’s journey.” · word for word

Integration risk; regulatory and stockholder approvals required; closing expected Q4 2026

“Transaction subject to customary regulatory approvals, BioLife stockholder approval, and other closing conditions”

Divestiture loss

“Loss on sale of business $13,763 thousand for the three months ended March 31, 2026.”

Foreign exchange exposure

“Foreign currency translation adjustment loss of $11,665 thousand for the three months ended March 31, 2026.”

Restructuring execution risk

“Restructuring activities to simplify manufacturing footprint; charges expected to be substantially complete by end of 2027.”

Divestiture of Polymem creates a small revenue headwind for FY26 guidance

“The business generated $7 million of revenue and an operating loss in 2025. FY26 guidance now reflects this divestiture.” · word for word

Transformation Office initiatives may involve execution risk

“Launched Transformation Office, focused on accelerating our fit-for-growth journey and our commitment to margin expansion. This includes efforts around site rationalization, product line margin optimization, and accelerating IT and AI investments”

PSU Performance Miss

“These PSU awards were not earned due to not achieving the organic revenue growth goal or Adjusted ROIC goal for the PSU awards. Base Organic Revenue Growth 2023-2025: Achievement 2.6%, Payout 0.0%. Adjusted ROIC: Achievement 4.4%, Payout 0.0%.” · word for word

Low Insider Ownership

“All directors, nominees and executive officers as a group (13 persons) 329,742 shares, 0.6%.” · word for word

M&A Dilution to Margins

“While foreign currency was favorable, this was offset by dilution from M&A, which weighed on operating margin expansion.” · word for word

Tariff Headwinds

“We expanded adjusted gross margin by approximately 2.2%, driven by volume and price, which offset inflation, tariff, and mix headwinds.” · word for word

Material weaknesses in internal controls

“As previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, the Company identified the following material weaknesses in internal control over financial reporting: 1. Management identified deficiencies related to the design and operating effectiveness of controls related to revenue recognition specific to the eval” · word for word

High debt level and refinancing risk

“In December 2023, we incurred significant indebtedness with the issuance of $600.0 million in aggregate principal amount of 1.00% Convertible Senior Notes due 2028... As of December 31, 2025, $600.0 million in aggregate principal amount of the 2023 Notes remain outstanding.” · word for word

Foreign exchange risk

“For the fiscal year ended December 31, 2025, 39.5% of our revenues were denominated in foreign currencies with the primary foreign currency exposures being the Euro, South Korean Won and Japanese Yen.” · word for word

Customer concentration risk

“Although we do not currently have any customers that represent more than 10% of our consolidated revenues, the loss of, or a significant reduction in orders from, any of our large customers, including following any termination or failure to renew a long-term supply contract, would significantly reduce our revenues and harm our results of operations.” · word for word

Gene therapy headwind of ~2 points in FY2026 guidance; potential for further delays in customer programs.

“includes a two-point gene therapy headwind” · word for word

Foreign exchange and M&A impacts could affect reported results; guidance excludes future acquisitions.

“Revenue guidance reflects just under a one point benefit from foreign currency and M&A.” · word for word

Leadership transition may cause short-term uncertainty, but orderly succession mitigates risk.

“Retirement of Executive Chair Tony Hunt; Dr. Madaus has deep industry experience.”

Material Weaknesses in Internal Control Over Financial Reporting

“As previously disclosed in the Form 10-K, the Company identified the following material weaknesses in internal control over financial reporting: ... As of September 30, 2025, the Company has not remediated these material weaknesses.” · word for word

Convertible Debt Overhang

“Convertible Senior Notes due 2028, net $537,927”

Foreign Exchange Exposure

“We are therefore subject to non-U.S. exchange exposure. Exchange rates can be volatile and a substantial weakening or strengthening of foreign currencies against the U.S. dollar could increase or reduce our revenue and gross profit margin and impact the comparability of results from period to period.” · word for word

No significant risks identified; strong execution and demand.

“All franchises posted double-digit growth; guidance raised.”